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ABSTRACT
Background
Ovarian cancer has a poor prognosis due to advanced stage at presentation and either
intrinsic or acquired resistance to classic cytotoxic drugs such as platinum and taxoids. Recent
large clinical trials with different combinations and sequences of classic cytotoxic drugs
indicate that further significant improvement in prognosis by this type of drugs is not to be
expected. Currently a large number of drugs, targeting dysregulated molecular pathways in
cancer cells have been developed and are introduced in the clinic. A major challenge is to
identify those patients who will benefit from drugs targeting these specific dysregulated
pathways.The aims of our study were (1) to develop a gene expression profile associated with
overall survival in advanced stage serous ovarian cancer, (2) to assess the association of
pathways and transcription factors with overall survival, and (3) to validate our identified profile
and pathways/transcription factors in an independent set of ovarian cancers.
Methods and Findings
According to a randomized design, profiling of 157 advanced stage serous ovarian cancers
was performed in duplicate using ;35,000 70-mer oligonucleotide microarrays. A continuous
predictor of overall survival was built taking into account well-known issues in microarray
analysis, such as multiple testing and overfitting. A functional class scoring analysis was utilized
to assess pathways/transcription factors for their association with overall survival. The
prognostic value of genes that constitute our overall survival profile was validated on a fully
independent, publicly available dataset of 118 well-defined primary serous ovarian cancers.
Furthermore, functional class scoring analysis was also performed on this independent dataset
to assess the similarities with results from our own dataset. An 86-gene overall survival profile
discriminated between patients with unfavorable and favorable prognosis (median survival, 19
versus 41 mo, respectively; permutation p-value of log-rank statistic¼0.015) and maintained its
independent prognostic value in multivariate analysis. Genes that composed the overall
survival profile were also able to discriminate between the two risk groups in the independent
dataset. In our dataset 17/167 pathways and 13/111 transcription factors were associated with
overall survival, of which 16 and 12, respectively, were confirmed in the independent dataset.
Conclusions
Our study provides new clues to genes, pathways, and transcription factors that contribute
to the clinical outcome of serous ovarian cancer and might be exploited in designing new
treatment strategies.
The Editors’ Summary of this article follows the references.
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Ovarian carcinoma is the leading cause of death from
gynecologic malignancies in the Western world [1]. Debulking
surgery followed by platinum-based chemotherapy is consid-
ered standard of care for patients with advanced stage
ovarian cancer, but despite an initial response rate of 65%–
80% to ﬁrst-line chemotherapy, most patients will relapse
with drug-resistant disease [2]. Consequently, the 5-y survival
rate of patients with advanced-stage disease is only about
5%–30% [3].
To date, a variety of studies have employed gene expression
proﬁling to classify ovarian carcinomas in clinically relevant
subtypes [4–9]. These studies provided valuable ﬁrst clues to
molecular changes in serous ovarian cancer that might be
exploited in new treatment strategies. However, most studies
were of relatively limited size and the number of overlapping
genes in the identiﬁed proﬁles was minimal. Although
identiﬁcation of gene expression proﬁles associated with
clinically relevant subtypes in ovarian cancer is important,
knowledge is now rapidly emerging on how genes interact in
pathways, networks and complexes; this new information
allows us to unravel the cellular pathways determining the
biological behavior of ovarian cancer, and these pathways
might be successfully targeted with drugs.
The aim of our study was to (1) develop a gene expression
proﬁle associated with overall survival in advanced-stage
serous ovarian cancer, (2) assess the association of pathways
and transcription factors with overall survival, and (3)
validate our proﬁle and identiﬁed pathways/transcription
factors in a fully independent, publicly available dataset of
serous ovarian cancers.
Materials and Methods
Patients and Tumor Samples
The study population consisted of 157 consecutive patients
with advanced-stage serous ovarian cancer operated on by a
gynecologic oncologist from the University Medical Center
Groningen (UMCG, Groningen, The Netherlands) in the
period 1990–2003. All patients were treated according to
Dutch guidelines, which are based on the International
Federation of Gynecology and Obstetrics (FIGO) guidelines
[10,11]. Standard treatment included cytoreductive surgery
followed by platinum-based chemotherapy (in combination
with paclitaxel after 1996). For follow-up, patients were seen
every 3 mo for the ﬁrst 2 y. Thereafter, follow-up visits had an
interval of 4 mo in the third year, 6 mo in the fourth and ﬁfth
year, and once a year in the sixth to tenth year. A follow-up
visit comprised a general physical and gynecologic examina-
tion. CA125 serum levels were also routinely determined.
Overall survival was calculated from the date of primary
surgery to the date of last follow-up (right-censored) or to the
date of death due to ovarian cancer. Patients who died from
intercurrent disease were right-censored at the time of death.
All tumor samples were obtained at primary surgery prior to
chemotherapy, ﬂash frozen in liquid nitrogen, and stored at
 80 8C. Samples were conﬁrmed to comprise tumor cells
(median percentage tumor cells: 70%, interquartile range:
50%–80%), as examined after hematoxylin and eosin staining
of frozen sections. Patients gave informed consent for
collection and storage of tissue samples in a tissue bank for
future research. All relevant patient data were retrieved and
transferred into an anonymous, password-protected, data-
base. The patients’ identity was protected by study-speciﬁc,
unique patient codes and their true identity was only known
to two dedicated data managers. According to Dutch
regulations, these precautions meant no further institutional
review board approval was needed (http://www.federa.org/).
RNA Extraction and Amplification
Total RNA from tumor samples was subjected to cesium
chloride density gradient ultracentrifugation (Roche, Almere,
The Netherlands). After total RNA samples had been given
DNAse treatment (Megascript T7 kit, Ambion, Huntingdon,
UK), they were checked for residual DNA using a dinucleo-
tide primer set (D11S875) speciﬁc for genomic DNA [12].
mRNA was linearly ampliﬁed by in vitro transcription using
T7 RNA polymerase (Megascript T7 kit) [13]. Quality/integrity
of total and ampliﬁed mRNA (cRNA) was checked by
spectrophotometric analysis (criterion: UV 260/280 ratio .
1.8 for each sample), and/or agarose gel electrophoresis.
Microarray Experiments
Two randomly selected cRNA samples were hybridized
together on the arrays for intensity-based instead of ratio-
based analysis of the microarray data [14]. All cRNA samples
(1.5 lg) were labeled with ULS-Cy5 and ULS-Cy3 label
(BIOKE ´, Leiden, The Netherlands) and hybridized to
;35,000 70-mer two-color oligonucleotide microarrays
(;35,000 Operon v3.0 probes), manufactured by The Nether-
lands Cancer Institute (Amsterdam, The Netherlands, http://
microarrays.nki.nl) [13]. Because each tumor sample was
proﬁled once with Cy5 and once with Cy3, there was one
replicate of the whole experiment. Samples were hybridized
according to a randomized design (Figure S1) to prevent
systematic biases such as those caused by batch effects or
technical variation that can be introduced during labeling,
hybridization, and scanning [15–17]. After randomization of
the processing order of the arrays from different batches,
Cy5- and Cy3-labeled cRNA samples were randomly placed
onto the arrays. Arrays were scanned and expression values
were calculated. The MIAME-compliant microarray data are
available at http://www.ncbi.nlm.nih.gov/geo/ under accession
number GSE13876.
Quantitative Real Time-PCR
Total RNA from 31 specimens, previously extracted,
isolated, and used for the microarray study, was reverse
transcribed into cDNA using MMLV reverse transcriptase and
hexameric random primer pd(N)6 (Invitrogen, Breda, The
Netherlands). The proﬁle of the reverse transcription reaction
was 10 min at 25 8C, 50 min at 37 8C, and 15 min at 70 8C.
Quantitative real-time PCR (qRT-PCR) was performed on
12 ng of cDNA. Applied Biosystems Taqman Gene expression
assays, and Taqman Universal PCR master mix (Applied
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) were
used to perform qRT-PCR on FGFBP1 (Hs00183226_m1,
Applied Biosystems), TMEM45A (Hs01046616_m1, Applied
Biosystems), FKBP7 (Hs00383941_m1, Applied Biosystems),
CCL28 (Hs00955110_m1, Applied Biosystems), and the
housekeeping gene GAPDH (Hs02758991_g1, Applied Bio-
systems), which is among the most constantly expressed
mRNAs [18]. All reactions were performed in 384-well plates
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Detection System. PCR reaction conditions were as follows:
Step 1: 50 8C for 2 min, step 2: 95 8C for 10 min, step 3: 50
cycles of 95 8C for 15 s, followed by 60 8C for 1 min. We used
the comparative threshold cycle (Ct) method to calculate the
expression of the gene of interest relative to GAPDH in each
sample by subtracting the mean Ct value of GAPDH from the
mean Ct value of each gene, obtaining the DCt value.
Statistical Methods
Quantile normalization was applied to log2-transformed
Cy5 and Cy3 intensities [19]. The goal of the quantile
normalization is to equalize the distribution of expression
values for each array in a set of arrays: (1) expression values of
each microarray were sorted, (2) median intensity in each rank
across the microarrays was computed, and (3) each expression
value was replaced by the median intensity at its rank.
Principal components analysis (PCA) was performed for
quality control. It has been shown that the most signiﬁcant
principal component for a gene expression data matrix is
frequently a constant pattern, which dominates the data [20].
So, the ﬁrst principal component explaining the largest part
of the variation could be considered variation that the arrays
have in common [21,22]. Next, correlation with the ﬁrst
principal component was calculated for each individual array
(factor loading). Factor loadings of the ﬁrst principal
component for an individual array can be seen as a quality
index, as arrays of lesser quality would have lower or
distinctly different correlations than arrays of good quality.
Samples with a factor loading with the ﬁrst principal
components of less than 2 times the standard deviation from
the mean were excluded as their hybridizations were
considered to be of low quality [21,22]. Operon V3.0 probe
identiﬁers (;35,000) were converted to ofﬁcial gene symbols
using probe annotations provided by The Netherlands
Cancer Institute (http://microarrays.nki.nl//download/ﬁles/
operon_hs_060614.xls). A description of the annotation
methodology used by The Netherlands Cancer Institute is
provided on their Web site (http://microarrays.nki.nl/services/
blastdata.html). We have only used those oligonucleotides
that speciﬁcally respond in a BLAST search with a single hit
on a gene. Expression values of multiple oligonucleotide
probes targeting the same gene (identical gene symbol) were
averaged, resulting in a total of 15,909 unique genes for
further analysis. Subsequently, expression data obtained from
Cy5- and Cy3-labeled samples of the same tumor were
averaged (mean correlation 0.93 6 standard deviation 0.04).
Microarray analyses were performed with the software
package BRB Array Tools 3.6.0, developed by the Biometric
Research Branch of the US National Cancer Institute (http://
linus.nci.nih.gov/BRB-ArrayTools.html).
Survival prediction. An overall survival proﬁle was built
using the supervised principal components method [23]. For
each iteration of the complete cross-validation, 10% of the
cases were omitted, and a subset of genes was selected that
correlated with overall survival at a signiﬁcance level of p ,
0.001 for the remaining cases. The signiﬁcance of each gene
was measured based on a univariate Cox proportional
hazards regression of survival time versus the log expression
level. Next, PCA was performed to reduce the dimensionality
of this selected subset of genes. Principal components (PCs),
which are linear additions of weighted gene expression
signals, were constructed in such a way that the ﬁrst PC
explained the largest amount of variance in our dataset and
each subsequent PC explained the largest amount of the
remaining variance while remaining uncorrelated with the
previously constructed PC. Cox proportional hazards model
was ﬁtted to the data (with 10% of cases omitted) using the
ﬁrst ﬁve PCs as predictor variables, providing a regression
coefﬁcient (weight) for each principal component. The
regression coefﬁcients in combination with the ﬁrst ﬁve PCs
were used to calculate the predictive index for each sample.
The 10% omitted test cases were classiﬁed as high or low risk
based on whether their predictive index was above or below
the median of the predictive indices for the 90% of cases in
the training set. This entire procedure was repeated, leaving
out a different 10% of cases until each case had been omitted
exactly once and the cross-validated risk groups were
determined for all cases. So the cross-validated risk group
for each case was determined based on a predictor model that
did not use that case in any way in its construction.
Kaplan-Meier survival curves were plotted for the pre-
dicted overall survival risk classes (high or low) giving a fair
representation of the value of the expression proﬁles for
predicting overall survival risk and the log-rank statistic was
computed. To assess the signiﬁcance of the log-rank statistic
and the degree of overﬁtting, a phenotype permutation test
based on 1,000 permutations was performed [24]. Survival
data were randomly shufﬂed among the cases and the entire
cross-validation process described above was repeated. For
each random reshufﬂing, the process was repeated, new cross-
validated Kaplan-Meier survival curves created, and the log-
rank statistic for the random shufﬂing was computed,
providing a null-distribution of the log-rank statistic. The
tail area of this null distribution beyond the log-rank statistic
obtained from the real data was the permutation signiﬁcance
level for testing the null hypothesis of no relation between the
expression data and overall survival. A graphical representa-
tion of the survival prediction method is given in Figure S2.
The genes that are selected as univariately associated with
survival will differ for each iteration of the cross-validation,
because the entire predictor development process must be
repeated from the beginning for each new cross-validated
training set. The ﬁnal gene set (proﬁle) presented in the results
was selected when the supervised principal components
methodwasappliedtothefulldatasetwithnosamplesomitted.
Furthermore, to evaluate whether our proﬁle provides
more accurate predictions than that provided by standard
clinicopathological covariates we performed a multivariate
analysis using Cox proportional hazards regression.
Pathway and transcription factor analysis. Functional gene
set enrichment analysis was performed as described by
Pavlidis et al. [25]. Predeﬁned gene sets were analyzed to
indicate which contained more genes correlated with overall
survival than would be expected by chance. First a univariate
Cox proportional hazards p-value was computed for all 15,909
unique genes. Then p-values of a subset of genes belonging to
a functional set were summarized by the LS and KS summary
statistics. For a set of n genes, the LS statistic is deﬁned as the
mean negative natural logarithm of single gene p-values. The
KS statistic is deﬁned as the maximum difference between i/n
and pi, where pi is the i
th smallest p-value. This is the
Kolmogorov-Smirnov statistic for testing if the p-values are of
uniform distribution. The statistical signiﬁcance of a func-
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the empirical distribution of these summary statistics in
random samples of n genes. A total of 167 functional gene sets
reported in the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database and 111 reported in the Transcriptional
Regulatory Element Database (TRED) were analyzed [26,27].
External validation. To establish that our proﬁle was
associated with prognosis in an independent set of serous
ovarian cancers, we used publicly available microarray data
[4,9,28]. Available clinicopathologic characteristics of the 118
patients as reported previously are summarized in Table S1.
Differences in microarray platforms (Operon V3 versus
Affymetrix HU133A) meant that direct application of our
prediction model on this independent dataset was not
feasible [29]. The platforms differ, for example, in the
reporter systems (short versus long oligonucleotides), labeling
techniques, and hybridization protocols. Furthermore, many
probes from the two platforms assigned to the same gene
symbol are in fact detecting different splicing variants.
Therefore, the genes composing our proﬁle, but not the
prediction rule, were generalizable to the independent
dataset using a previously described methodology [30]. Probe
sets from the Affymetrix HU133A microarray related to the
genes in our proﬁle were selected. Subsequently, we applied
the survival prediction method, with cross-validation and
permutation testing as described above, to assess the
performance of a classiﬁer for the independent dataset based
only on these selected probes; however, this time a
signiﬁcance threshold of 0.9999 was used to ensure that all
selected probes representing genes from our survival proﬁle
were used in each iteration of the cross-validation. Further-
more, functional class scoring analysis for pathways and
transcription factors as described above using all available
probes was also performed on this independent dataset to
compare results [25].
Oncogenic pathway activation analysis. Recently, Bild et al.
experimentally generated expression signatures that reﬂect
the activation of various oncogenic signaling pathways, and
provided software to assess the activation status in individual
expression proﬁles [28]. We used these publicly available
expression proﬁles and software to assess the activation
probability of the c-Myc, H-Ras, c-Src, E2F3, and b-catenin
pathway in our 157 ovarian tumor samples. For each pathway
we divided the tumor samples into a group with an activation
probability p , 0.5 and a group with activation probability p
. 0.5. Next, Kaplan-Meier survival curves were plotted for
both groups and the log-rank statistic computed. A signiﬁcant
log-rank statistic would indicate an association between the
activation status of the oncogenic pathway and overall
survival. Furthermore, to assess the combined effect of the
ﬁve oncogenic pathways on overall survival, we applied
average linkage hierarchical clustering according to the
uncentered correlation measure on the activation probabil-
ities. Kaplan-Meier survival curves were plotted for the top
two clusters and the log-rank statistic was computed.
Results
Patient Characteristics
Clinicopathologic characteristics of the 157 platinum-
treated patients with serous ovarian cancer are summarized
in Table 1. For the whole group the median overall survival
time was 21 mo (range 1–234 mo), and the 5-y overall survival
rate was 27%.
Table 1. Patient Characteristics (n ¼ 157)
Characteristic Category or Measure n or Value Percentage
Age, y Median (range) 60 (21–84) —
Survival, mo Median (range) 21 (1–234) —
Stage (FIGO) IIIA 2 1.3
IIIB 6 3.8
IIIC 125 79.6
IV 24 15.3
Grade Well differentiated 14 8.9
Moderately differentiated 45 28.7
Poorly differentiated 82 52.2
Undifferentiated 3 1.9
Unknown 13 8.3
Debulking status Complete debulking 22 14
, 2 cm 21 13.4
  2 cm 100 63.7
Positive, size unknown 9 5.7
Unknown 5 3.2
Chemotherapy Carboplatin 2 1.2
Cyclophosphamide/carboplatin 88 56.1
Cyclophosphamide/cisplatin 12 7.6
Paclitaxel/cisplatin 7 4.5
Paclitaxel/carboplatin 48 30.6
Ascites , 1 L 49 31.2
  1 L 71 45.2
Unknown 37 23.6
All patients received platinum-based chemotherapy postoperatively.
doi:10.1371/journal.pmed.1000024.t001
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Gene Symbol p-Value %CV Support
a Hazard Ratio Description
AAK1 0.000645 40 0.48 AP2 associated kinase 1
ACSM1 0.000361 60 0.27 Acyl-CoA synthetase medium-chain family member 1
AGPAT7 0.000418 60 0.33 1-Acylglycerol-3-phosphate O-acyltransferase 7 (lysophosphatidic acid
acyltransferase, eta)
AIPL1 0.000989 30 0.38 Aryl hydrocarbon receptor interacting protein-like 1
ATP5D 0.000133 90 0.52 ATP synthase, Hþ transporting, mitochondrial F1 complex, delta subunit
BAX 0.000964 50 0.39 BCL2-associated X protein
BRSK1 0.000981 30 0.63 BR serine/threonine kinase 1
C10orf80 0.000407 40 0.35 Chromosome 10 open reading frame 80
C14orf121 0.000105 90 0.26 Chromosome 14 open reading frame 121
C1orf151 0.000116 90 0.58 Chromosome 1 open reading frame 151
C1orf159 0.000228 70 0.30 Chromosome 1 open reading frame 159
C1orf198 0.000785 30 1.61 Chromosome 1 open reading frame 198
C1orf68 0.000348 50 0.47 Chromosome 1 open reading frame 68
C1QTNF3 0.000106 90 1.75 C1q and tumor necrosis factor related protein 3
C20orf32 0.000699 40 0.58 Chromosome 20 open reading frame 32
CACNA1B 0.000027 100 0.32 Calcium channel, voltage-dependent, N type, alpha 1B subunit
CACNG6 0.000154 80 0.40 Calcium channel, voltage-dependent, gamma subunit 6
CCDC135 0.000232 70 0.30 Coiled-coil domain containing 135
CCL28 0.000749 40 1.48 Chemokine (C-C motif) ligand 28
CDH19 0.000493 40 0.45 Cadherin 19, type 2
CDYL2 0.000987 20 0.49 Chromodomain protein, Y-like 2
CES2 0.000256 60 0.39 Carboxylesterase 2 (intestine, liver)
CNTFR 0.00071 40 0.45 Ciliary neurotrophic factor receptor
CPE 0.000651 40 1.42 Carboxypeptidase E
CRYBB1 0.000473 50 0.34 Crystallin, beta B1
DDB2 0.000937 40 0.64 Damage-specific DNA binding protein 2, 48kDa
FEZ1 0.000451 50 2.2 Fasciculation and elongation protein zeta 1 (zygin i)
FGFBP1 0.000525 50 0.73 Fibroblast growth factor binding protein 1
FGFR1OP2 0.000428 50 1.77 FGFR1 oncogene partner 2
FKBP7 0.000042 100 2.90 FK506 binding protein 7
GCM1 0.000638 40 0.41 Glial cells missing homolog 1 (drosophila)
GNAZ 0.000256 70 0.32 Guanine nucleotide binding protein (G protein), alpha z polypeptide
HIPK1 0.00044 70 0.20 Homeodomain interacting protein kinase 1
ITGB7 0.000023 100 0.39 Integrin, beta 7
JAK2 0.000811 60 0.41 Janus kinase 2 (a protein tyrosine kinase)
KDELR2 0.000566 40 1.73 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2
KIAA0141 0.000283 60 0.51 KIAA0141
KLF12 0.00045 50 2.71 Kruppel-like factor 12
KLHL7 0.000842 40 2.49 Kelch-like 7 (drosophila)
KRT10 0.000802 40 1.80 Keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris)
KYNU 0.000342 80 0.49 Kynureninase (L-kynurenine hydrolase)
LIN28 0.000089 100 2.12 Lin-28 homolog (C. elegans)
LRRC17 0.000691 40 1.51 Leucine-rich repeat containing 17
LRSAM1 0.000397 60 0.38 Leucine-rich repeat and sterile alpha motif containing 1
METTL4 0.000828 40 0.46 Methyltransferase like 4
MFAP2 0.000198 80 1.77 Microfibrillar-associated protein 2
MUTYH 0.000619 40 0.34 MutY homolog (E. coli)
MXD1 0.000057 100 0.40 MAX dimerization protein 1
NANOS1 0.000275 70 1.80 Nanos homolog 1 (drosophila)
NCR2 0.000425 80 0.35 Natural cytotoxicity triggering receptor 2
ODF4 0.000094 80 0.43 Outer dense fiber of sperm tails 4
OR10A3 0.000023 90 0.49 Olfactory receptor, family 10, subfamily A, member 3
OR2AG1 0.000435 60 0.41 Olfactory receptor, family 2, subfamily ag, member 1
OR4C15 0.000931 40 0.40 Olfactory receptor, family 4, subfamily c, member 15
OR51B5 0.00062 40 0.47 Olfactory receptor, family 51, subfamily B, member 5
OR51I1 0.000042 100 0.63 Olfactory receptor, family 51, subfamily I, member 1
OR6F1 0.000866 30 0.40 Olfactory receptor, family 6, subfamily F, member 1
OR9G9 0.000512 40 0.45 Olfactory receptor, family 9, subfamily G, member 9
OSGEPL1 0.000443 50 2.05 O-sialoglycoprotein endopeptidase-like 1
OSM 0.000645 40 0.62 Oncostatin M
PKHD1 0.000882 20 0.32 Polycystic kidney and hepatic disease 1 (autosomal recessive)
PPAP2B 0.000695 40 1.39 Phosphatidic acid phosphatase type 2B
PPCDC 0.000021 100 0.34 Phosphopantothenoylcysteine decarboxylase
PRELP 0.00043 50 1.34 Proline/arginine-rich end leucine-rich repeat protein
PTCH2 0.0002 80 0.43 Patched homolog 2 (drosophila)
PTPRN2 0.000265 60 0.43 Protein tyrosine phosphatase, receptor type, N polypeptide 2
RIN1 0.000285 70 0.44 Ras and Rab interactor 1
RIT1 0.000282 70 1.91 Ras-like without CAAX 1
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Eighty-six genes were found to correlate with overall
survival by univariately ﬁtting Cox proportional models at
an alpha of 0.001. In Table 2 each gene is listed with its p-
value, cross-validation support, hazard ratio (HR), and
description. Univariate p-values, HR, and false discovery rates
(FDRs) for all 15,909 genes are given in Table S2. The FDR
associated with a row of the table is an estimate of the
proportion of the genes with univariate p-values less than or
equal to the one in that row that represent false positives [31].
Figure 1A shows the Kaplan-Meier survival curves for the
cross-validated risk groups predicted to have above (n¼83) or
below (n ¼ 74) median risk of death due to ovarian cancer.
Table S3 contains the necessary weights and ﬁnal prediction
rule to calculate the predictive index for a sample based on
the expression signals of the identiﬁed 86 genes. As
mentioned in the methods section the cross-validated risk
group for each case was determined based on a predictor
model that did not use that case in any way in its
construction. The low-risk group had a median survival of
41 mo, whereas the high-risk group had a median survival of
19 mo (p ¼ 0.0014, log-rank). The permutation test based on
1,000 permutations resulted in a p-value of 0.0015, indicating
that the chance that such a log-rank static is based on
overﬁtting is small. Table 3 shows the distribution of several
prognostic factors as a function of risk assignment based on
our 86-gene overall survival proﬁle. Age, stage, grade,
debulking status, and chemotherapy regimens showed no
difference in distribution between the predicted low- and
high-risk groups. In addition to our overall survival proﬁle,
only the amount of residual tumor after primary surgery (p¼
0.0003; HR ¼ 2.34) showed a prognostic value for overall
survival in univariate analysis. In multivariate analysis our
overall survival proﬁle (p¼0.008; HR¼1.94; 95% conﬁdence
interval [CI] 1.19–3.16) and debulking status (p ¼ 0.006; HR ¼
2.44; 95% CI 1.30–4.60) both maintained independent
prognostic signiﬁcance (Table 4).
QRT-PCR Validation of the Overall Survival Profile
To validate the overall survival proﬁle, we performed qRT-
PCR for 31 total RNA samples that had been included in the
microarray analysis. Four genes, i.e., FGFBP1, FKBP7, TME-
M45A, and CCL28, that differ in percentage cross-validation
support were arbitrarily selected from the 86-gene overall
survival proﬁle. Relative expression levels for each gene were
correlated with the corresponding microarray signal inten-
sities. A strong correlation between qRT-PCR and microarray
signal intensities was observed for all four genes (Figure 2).
Independent Validation of the Overall Survival Profile
Because of the different microarray platforms used, our
predictor model could not be directly tested on the
independent serous ovarian cancer dataset. Instead we
identiﬁed 97 probes on the HU133A platform, targeting 57
out of the 86 unique genes from our overall survival proﬁle.
T h e s ep r o b e sw e r eu s e dt ob u i l das u r v i v a lp r o ﬁ l ea s
described above. Figure 1B shows the Kaplan-Meier survival
curves for the patients from the independent dataset
predicted to have above or below median risk of death due
to ovarian cancer. This low-risk group had a median survival
of 108 mo, whereas the high-risk group had a median survival
of 33 mo (p , 0.0001, log-rank). The permutation p-value of
the log-rank test statistic between the two risk groups, based
on 1,000 permutations, was p ¼ 0.007.
Pathways and Transcription Factors Associated with
Overall Survival
As input for the survival gene set analysis, signiﬁcance
levels based on univariate Cox proportional hazards regres-
sion of survival time versus the log expression level for all
15,909 genes were used. KEGG pathways and transcription
factors associated with overall survival in our dataset and that
Table 2. Continued.
Gene Symbol p-Value %CV Support
a Hazard Ratio Description
SCO2 0.000263 70 0.46 SCO cytochrome oxidase deficient homolog 2 (yeast)
SEPN1 0.000093 100 0.40 Selenoprotein N, 1
SIGLEC8 0.000838 20 0.48 Sialic acid binding Ig-like lectin 8
SMPD2 0.000049 90 0.47 Sphingomyelin phosphodiesterase 2, neutral membrane
(neutral sphingomyelinase)
SPATA13 0.000631 50 0.46 Spermatogenesis associated 13
SPATA18 0.000139 80 0.38 Spermatogenesis associated 18 homolog (rat)
SYT11 0.000838 40 1.69 Synaptotagmin XI
TMEM150 0.000425 40 0.30 Transmembrane protein 150
TMEM45A 0.000288 70 1.49 Transmembrane protein 45A
TRO 0.000051 100 2.17 Trophinin
TRPV4 0.000999 10 0.53 Transient receptor potential cation channel, subfamily V, member 4
TUBB4 0.00071 30 0.43 Tubulin, beta 4
WDR7 0.000086 100 0.26 WD repeat domain 7
WNT16 0.000828 30 0.48 Wingless-type MMTV integration site family, member 16
ZBTB8 0.000324 80 2.26 Zinc finger and BTB domain containing 8
ZNF12 0.000588 30 2.05 Zinc finger protein 12
ZNF521 0.000281 70 1.50 Zinc finger protein 521
ZNF569 0.000197 80 2.49 Zinc finger protein 569
a%CV Support indicates the percentage of the cross-validation training sets in which the gene was selected. 100% means that the gene was selected in all of the cross-validated training
sets.
doi:10.1371/journal.pmed.1000024.t002
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respectively. In our dataset 17/167 pathways and 13/111
transcription factors were associated with overall survival,
of which 16 and 12, respectively, were conﬁrmed in the
independent dataset from Dressman et al. [9]. Table S4 shows
univariate p-values and hazard ratios for genes that form part
of the 17 pathways associated with overall survival in our
dataset.
Oncogenic Pathway Activation
Figure 3 shows a heatmap of the predicted activation status
for the ﬁve oncogenic pathways in our 157 ovarian tumor
samples. Red indicates a high probability of activation and
green indicates a low probability of activation. None of the
ﬁve oncogenic pathways showed a signiﬁcant log-rank
statistic for the Kaplan-Meier survival curves between the
group of ovarian tumor samples with an activation proba-
bility p , 0.5 and the group with an activation probability p .
0.5. The ﬁve Kaplan-Meier curves and the associated log-rank
p-values are shown in Figure S3. After clustering the samples
on their activation probabilities for the ﬁve oncogenic
pathways combined, the top two clusters showed no
signiﬁcant difference between their Kaplan-Meier survival
curves (Figure S4).
Discussion
In this study on tumors of a large series of well-documented
advanced-stage serous ovarian cancer patients we identiﬁed a
gene expression proﬁle that reﬂects patients’ overall survival.
Our overall survival proﬁle maintained independent prog-
Figure 1. Kaplan-Meier Survival Curves for the Patients Predicted to Have Above or Below Median Risk of Death Due to Ovarian Cancer
(A) Present study, median survival of 19 mo versus 41 mo (p ¼ 0.0014, log-rank), permutation p-value ¼ 0.015.
(B) Dressman et al. [9], median survival of 33 mo versus 108 mo (p , 0.0001, log-rank), permutation p-value ¼ 0.007.
doi:10.1371/journal.pmed.1000024.g001
Table 3. Association between the Overall Survival Profile and Clinicopathologic Characteristics
Characteristic Subcategory Low Risk (n ¼ 74) High Risk (n ¼ 83) p-Value
n or Value % n or Value %
Age Median, years 60 — 60 — —
Survival Median, months 41 — 19 — —
Stage (FIGO) IIIA 2 2.7 0 0 0.128
IIIB 1 1.4 5 6 —
IIIC 62 83.8 63 75.9 —
IV 9 12.2 15 18.1 —
Grade Well differentiated 9 12.2 5 6 0.104
Moderately differentiated 16 21.6 29 34.9 —
Poorly differentiated 43 58.1 39 47 —
Undifferentiated 0 0 3 3.6 —
Unknown 6 8.1 7 8.4 —
Debulking status Complete debulking 12 16.2 10 12.1 0.237
, 2 cm 10 13.5 11 13.3 —
  2 cm 48 64.9 52 62.7 —
Positive, size unknown 1 1.4 8 9.6 —
Unknown 3 4.1 2 2.4 —
Chemotherapy Non paclitaxel-based 44 59.5 58 69.9 0.115
Paclitaxel-based 30 40.5 25 30.1 —
p-Values for stage, grade, debulking status,and chemotherapy were derived from the Pearson Chi-square test. p-Value for age was derived from the t-test.
FIGO, International Federation of Gynecology and Obstetrics.
doi:10.1371/journal.pmed.1000024.t003
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pression of the genes that composed our overall survival
proﬁle also held their prognostic value in an independent
dataset processed at a different institution using a different
microarray platform. Finally, in addition to individual genes,
we were also able to reproducibly identify and validate KEGG
pathways and TRED transcription factors associated with
overall survival.
Limited overlap with respect to individual genes, as
observed in comparable studies in other tumor types, was
also found between our overall survival proﬁle and those
reported in three previous ovarian cancer microarray studies
[4,7,32].
Nonreproducibility of prognostic proﬁles between differ-
ent microarray studies in the same tumor type can be
attributed to a variety of methodological issues [33,34]. Our
study speciﬁcally pays attention to methodological principles
such as randomization and replication. Thus, confounding
effects are avoided and unbiased estimation of differential
expression levels is provided. The three studies mentioned
above did not include a replication of the experiment [4,7,32].
In contrast to these studies, by using supervised PCA to build
prognostic proﬁles, we could consider survival a continuous
parameter, and patients were thus not forced into subgroups
that might not be biologically meaningful. Categorizing
patients a priori into a ‘‘low risk’’ and ‘‘high risk’’ subgroup
based on survival times might cause any future predictions
based on this model to be suspect when underlying,
unidentiﬁed, biologically different subgroups have consider-
able overlap in survival times.
Table 4. Prognostic Value of the Overall Survival Profile Adjusted for Debulking Status, Stage, Grade, Age, and Ascites by Cox
Proportional Hazards Regression
Prognostic Factor Multivariate p-Value HR 95% CI
OSP 0.008 1.940 1.190–3.163
Stage (III vs. IV) 0.144 1.540 0.863–2.746
Debulking status (residual tumor , vs . 2 cm) 0.006 2.443 1.296–4.604
Grade (I vs II/III) 0.545 1.160 0.717–1.878
Ascites (þ vs. -) 0.365 1.262 0.763–2.086
Age
a 0.287 1.011 0.991–1.030
aAge was analyzed as a continous variable.
OSP, overall survival profile.
doi:10.1371/journal.pmed.1000024.t004
Figure 2. Scatter Plots Showing the Microarray Expression Signal Versus the DCt Obtained by qRT-PCR for Four Individual Genes
Genes are FGFBP1, FKBP7, TMEM45A, and CCL28 from our overall survival profile. DCt of the gene is obtained by subtracting the mean Ct value of GAPDH
from the mean Ct value of the gene. Both axes are on log2 scale.
doi:10.1371/journal.pmed.1000024.g002
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genes (Table 2) that offer potential insight into mechanisms
associated with tumor behavior. The overall validity of our
approach is conﬁrmed by the observation that for some of
the genes in our proﬁle, earlier studies that utilized non–
array-based methodologies already indicated their relevance
in ovarian cancer. For example, high expression of the
proapoptotic BAX gene was associated with improved
prognosis in our study. Previously, a similar relation between
BAX expression and response to chemotherapy and overall
survival in ovarian cancer was reported by others [8,35–37].
Likewise, in our study, high expression of Ras inhibitor 1
(RIN1) and low expression of Ras-like without CAAX1 (RIT1)
were associated with better overall survival, which is in
agreement with previous work by others showing that
activated Ras contributes to the maintenance and growth of
ovarian carcinomas [38]. In addition to these already known
relevant genes in ovarian cancer our study reveals also
multiple new genes with a possible impact on tumor behavior
in ovarian cancer. For example OSM, JAK2, and CNTFR are
components of the Jak/STAT signaling pathway, which can
stimulate cell proliferation, differentiation, cell migration,
and apoptosis [39]. OSM has individually been identiﬁed as a
potent suppressor of tumor cell proliferation and inducer of
differentiation in multiple tissues [40]. FGFBP1 and FGFR1
interact with ﬁbroblast growth factors FGF1 and FGF2, and it
has been suggested that the ﬁbroblast growth factors could
serve as the angiogenic switch in human cancer [41–43].
Apart from having prognostic impact our analysis also sheds
light on previous unknown possible ‘‘druggable’’ targets in
ovarian cancer; FKBP7, with the highest hazard ratio for
individual genes in our study, appears to be especially of
interest because FKBPs can be targeted with mTOR inhibi-
tors [44].
Although individual genes such as those described above
may prove to be relevant for tumor behavior, it is often not
known in ovarian and other cancers whether large fold-
changes in individual genes will have more biological
relevance than will smaller but coordinated fold-changes in
a set of genes along a single pathway. Analysis of our
microarray data by integration of genes into functional gene
sets according to well-known biological pathways and tran-
scription factors enabled us to consider all available genomic
information rather than only genes passing a certain
signiﬁcance threshold, thus providing extra clues to which
signaling pathways and transcription factors contribute to
the clinical outcome of ovarian cancer. Bonome et al. [32]
recently also identiﬁed possible signaling events (pathways).
However, by using classical over-representation analysis of
functional gene sets within only a small subset of genes (57
probes) associated with overall survival, the authors dis-
regarded most of the genomic information available [32].
Our pathway analysis, which to our knowledge has not been
applied to ovarian cancer array datasets previously, revealed
17 pathways to be related to survival, of which 16 were
validated in the independent dataset. As previously men-
tioned, there is usually only limited overlap with respect to
individual genes between the prognostic proﬁles previously
published in (ovarian) cancer [45]. In contrast, integrating
genes in functional gene sets according to pathways and
Table 5. KEGG Pathways with More Genes Correlated with
Overall Survival Than Expected by Chance as Identified in the
Present Study and in the Dressman et al. [9] Dataset
KEGG
Pathway
Pathway Description Present
Study
Dressman
et al. [9]
hsa00190 Oxidative phosphorylation X X
hsa00230 Purine metabolism X X
hsa01430 Cell communication X X
hsa04020 Calcium signaling pathway X X
hsa04060 Cytokine-cytokine receptor interaction X X
hsa04110 Cell cycle X X
hsa04310 Wnt signaling pathway X X
hsa04360 Axon guidance X X
hsa04510 Focal adhesion X X
hsa04514 Cell adhesion molecules (CAMs) X X
hsa04530 Tight junction X X
hsa04630 Jak-STAT signaling pathway X X
hsa04650 Natural killer cell mediated cytotoxicity X X
hsa04670 Leukocyte transendothelial migration X X
hsa04810 Regulation of actin cytoskeleton X X
hsa04910 Insulin signaling pathway X X
hsa04020 MAPK signaling pathway X
Pathways that are significant at the nominal 0.005 level of the LS permutation test or KS
permutation test are listed. The following pathways are associated with survival only in
the study of Dressman et al. [9]: Colorectal cancer, Pyrimidine metabolism, Tryptophan
metabolism, Glycerophospholipid metabolism, Glycan structures – biosynthesis 1,
Ribosome, PPAR signaling pathway, Phosphatidylinositol signaling system, Neuroactive
ligand-receptor interaction, Apoptosis, TGF-beta signaling pathway, VEGF signaling
pathway, ECM-receptor interaction, Adherens junction, Gap junction, Antigen processing
and presentation, Toll-like receptor signaling pathway, Hematopoietic cell lineage, B cell
receptor signaling pathway, Long-term potentiation, Long-term depression, GnRH
signaling pathway, Adipocytokine signaling pathway, Epithelial cell signaling in
Helicobacter pylori infection, One carbon pool by folate, Methane metabolism,
Glycosphingolipid biosynthesis – ganglioseries, Glycosphingolipid biosynthesis – globos-
eries, Hedgehog signaling pathway, Glycan structures – biosynthesis 2, Neurodegener-
ative disorders, Regulation of autophagy.
doi:10.1371/journal.pmed.1000024.t005
Table 6. Transcription Factor Gene Sets with More Genes
Correlated with Overall Survival Than Expected by Chance as
Identified in the Present Study and in the Dressman et al. [9]
Dataset
Factor Name Accession
Number
Present
Study
Dressman
et al. [9]
C/EBPalpha T00105 X X
CREB T00163 X X
E2F-1 T01542 X X
E2F-4 T01546 X X
c-Ets-1 T00112 X X
AP-1 T00029 X X
c-Myb T00137 X X
CTF-1 T00176 X X
NF-kappaB(-like) T00591 X X
Sp1 T00759 X X
AP-2alphaA T00035 X X
p53 T00671 X X
E2F-2 T01544 X
NOTE. Transcription factor gene sets that are significant at the nominal 0.005 level of the
LS permutation test or KS permutation. The following transcription factor gene sets are
associated with survival only in the study of Dressman et al. [9], ATF-1, Egr-1, ER-alpha,
PEA3, HIF-1, POU2F1, PPAR-gamma1, RAR-alpha1, RAR-beta, RelA, Sp3, PU.1, USF1, USF2, NF-
IL6–2.
doi:10.1371/journal.pmed.1000024.t006
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overlap between our dataset and the independent dataset
with respect to prognostic impact. Our results therefore
indicate that assessment of prognostic proﬁles is more robust
by determination of coordinated expression of several
signaling pathways than of expression of individual genes.
Thus in the present study, cell cycle, Wnt, Jak-STAT, and
MAPK pathways, playing a role in apoptosis, proliferation,
differentiation, and/or cell cycle, were identiﬁed as having a
role in ovarian cancer; consistent with these results, aberrant
signaling of each of these pathways has been proposed as
contributing to ovarian carcinogenesis [46–50], again indicat-
ing the strength of our approach. Novel therapeutic options
are currently being explored that act on several signaling
pathways that we found to be associated with overall survival
in ovarian cancer. For example, Basica et al. recently
described activation of Wnt signaling in ovarian and breast
cancer cell lines and showed that Wnt antagonists dramati-
cally altered the biological behavior of these cells [51]. A
blocking antibody against FZD10, a cell membrane receptor
for Wnt, was shown to have strong antitumor effect in
xenografted tumors overexpressing FZD10 [52,53]. As in our
study, a dysregulated Wnt pathway and, more speciﬁcally,
overexpression of FZD10 and FZD7 (another member of the
Wnt cell-surface receptor family) were related to worse
prognosis, so this FZD10 blocking antibody may have clinical
potential by inhibiting the autocrine Wnt signalling pathway
in ovarian cancer.
Our transcription factor analysis also implicated several
transcription factors (Table 5) in ovarian cancer. With
different methodologies A2P-2alpha and c-Ets-1 have pre-
viously been associated with poor prognosis in ovarian cancer
[54–56]. Similarly, E2F transcription factors, members of the
C/EBP family, and CREB were demonstrated to play an
important role in ovarian carcinogenesis [57–60]. With the
exception of p53, most transcription factors are presently
difﬁcult to target. Our transcription factor analysis demon-
strated a positive prognostic impact for p53 as an ‘‘activated’’
transcription factor. In tumor cell lines activation of wild-
type p53 can be induced by the small molecule nutlin-3,
which antagonizes the function of the natural inhibitor of
wild-type p53 MDM2, resulting in enhanced apoptosis or cell
cycle arrest [61,62]. In combination, these observations tempt
one to speculate on a possible role for nutlin-3 in overcoming
resistance to chemotherapy, especially in those ovarian
cancers with a less activated p53 [61,63].
A limitation of functional gene set enrichment analysis as
performed in our study, however, is its inability to assess the
activation status of identiﬁed pathways in an individual
tumor sample. This gap is potentially ﬁlled by the strategy
described by Dressman et al. [9] and Bild et al. [28] (see also
Materials and Methods: Oncogenic pathway activation anal-
Figure 3. Heatmap Showing Predicted Probabilities of Pathway
Activation for the Five Oncogenic Pathways
Pathways are c-Myc, H-Ras, c-Src, E2F3, and b-catenin in our 157 ovarian
tumor samples. Red indicates a high probability of activation and green
indicates a low probability of activation. The probabilities of pathway
activation were clustered according to the uncentered correlation
measure. On the right of the figure the follow-up in months is depicted
followed by the censoring status for each of the 157 samples.
doi:10.1371/journal.pmed.1000024.g003
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oncogenic signaling pathways in 157 ovarian tumor samples
based on the activation observed in a mammalian cell line
following tranfection of adenovirus expressing human c-Myc,
activated H-Ras, human c-Src, human E2F3, or b-catenin. Bild
et al. showed in a series of 153 samples that activated E2F3, b-
catenin, and c-Src pathways were associated with poor overall
survival in ovarian cancer [28]. None of these ﬁve oncogenic
pathways showed a signiﬁcant association (as individual
pathways and/or in combination) with overall survival in
our dataset (see Figures S3 and S4). Our results therefore
indicate that analysis of pathway activation status until now is
not very robust and cannot be easily exchanged between
different studies, as was recently also described by others [64].
In this study the prognostic impact of 57 genes from our
proﬁle was validated within the independent dataset from
Dressman et al. [9], providing stronger evidence than before
that these genes are important in the biological behavior of
ovarian tumors. Platform differences did not allow one-to-
one exact validation of the underlying predictive algorithm.
Therefore, the clinical usefulness of our overall survival
predictor needs further validation. With regard to the
reproducibility issues between different microarray plat-
forms, it seems likely that in the future an array-based
prognostic tool will be based on a single platform. So, our
study might be considered a phase II study in which we
constructed a genetic proﬁle associated with overall survival
within the whole group of 157 patients according to statistical
principles such as cross-validation and permutation testing
[65]. As described above, such a study provides valuable clues
about the mechanisms underlying tumor behavior and clues
with respect to potential drug development targets (genes,
pathways, etc). To further evaluate the prognostic impact of
our proﬁle for individual patients, prospective studies need
to be performed. Another important issue that needs to be
addressed in such studies is the impact of intratumor
heterogeneity on reproducibility. Using a combination of
microsatellite analysis and SNP analysis Khalique et al.
recently showed that intratumor heterogeneity is a common
feature within epithelial ovarian cancer [66].
In conclusion, our study provides new, validated insights
into molecular changes in genes, pathways, and transcription
factors that are relevant for ovarian cancer behavior and that
should therefore be exploited in the search for new treatment
strategies towards patient-tailored therapy. In the future,
pathway activation analysis in individual tumors may guide
the choice of targeting drugs in ovarian cancer patients
[67,68], but its methodology needs to become more robust
before clinical relevance can be envisioned.
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Background. Ovarian cancer kills more than 100,000 women every year
and is one of the most frequent causes of cancer death in women in
Western countries. Most ovarian cancers develop when an epithelial cell
in one of the ovaries (two small organs in the pelvis that produce eggs)
acquires genetic changes that allow it to grow uncontrollably and to
spread around the body (metastasize). In its early stages, ovarian cancer
is confined to the ovaries and can often be treated successfully by
surgery alone. Unfortunately, early ovarian cancer rarely has symptoms
so a third of women with ovarian cancer have advanced disease when
they first visit their doctor with symptoms that include vague abdominal
pains and mild digestive disturbances. That is, cancer cells have spread
into their abdominal cavity and metastasized to other parts of the body
(so-called stage III and IV disease). The outlook for women diagnosed
with stage III and IV disease, which are treated with a combination of
surgery and chemotherapy, is very poor. Only 30% of women with stage
III, and 5% with stage IV, are still alive five years after their cancer is
diagnosed.
Why Was This Study Done? If the cellular pathways that determine the
biological behavior of ovarian cancer could be identified, it might be
possible to develop more effective treatments for women with stage III
and IV disease. One way to identify these pathways is to use gene
expression profiling (a technique that catalogs all the genes expressed
by a cell) to compare gene expression patterns in the ovarian cancers of
women who survive for different lengths of time. Genes with different
expression levels in tumors with different outcomes could be targets for
new treatments. For example, it might be worth developing inhibitors of
proteins whose expression is greatest in tumors with short survival times.
In this study, the researchers develop an expression profile that is
associated with overall survival in advanced-stage serous ovarian cancer
(more than half of ovarian cancers originate in serous cells, epithelial cells
that secrete a watery fluid). The researchers also assess the association of
various cellular pathways and transcription factors (proteins that control
the expression of other proteins) with survival in this type of ovarian
carcinoma.
What Did the Researchers Do and Find? The researchers analyzed the
gene expression profiles of tumor samples taken from 157 patients with
advanced stage serous ovarian cancer and used the ‘‘supervised
principal components’’ method to build a predictor of overall survival
from these profiles and patient survival times. This 86-gene predictor
discriminated between patients with favorable and unfavorable out-
comes (average survival times of 41 and 19 months, respectively). It also
discriminated between groups of patients with these two outcomes in
an independent dataset collected from 118 additional serous ovarian
cancers. Next, the researchers used ‘‘functional class scoring’’ analysis to
assess the association between pathway and transcription factor
expression in the tumor samples and overall survival. Seventeen of 167
KEGG pathways (‘‘wiring’’ diagrams of molecular interactions, reactions
and relations involved in cellular processes and human diseases listed in
the Kyoto Encyclopedia of Genes and Genomes) were associated with
survival, 16 of which were confirmed in the independent dataset. Finally,
13 of 111 analyzed transcription factors were associated with overall
survival in the tumor samples, 12 of which were confirmed in the
independent dataset.
What Do These Findings Mean? These findings identify an 86-gene
overall survival gene expression profile that seems to predict overall
survival for women with advanced serous ovarian cancer. However,
before this profile can be used clinically, further validation of the profile
and more robust methods for determining gene expression profiles are
needed. Importantly, these findings also provide new clues about the
genes, pathways and transcription factors that contribute to the clinical
outcome of serous ovarian cancer, clues that can now be exploited in the
search for new treatment strategies. Finally, these findings suggest that it
might eventually be possible to tailor therapies to the needs of individual
patients by analyzing which pathways are activated in their tumors and
thus improve survival times for women with advanced ovarian cancer.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
1000024.
  This study is further discussed in a PLoS Medicine Perspective by Simon
Gayther and Kate Lawrenson
  See also a related PLoS Medicine Research Article by Huntsman and
colleagues
  The US National Cancer Institute provides a brief description of what
cancer is and how it develops, and information on all aspects of
ovarian cancer for patients and professionals (in English and Spanish)
  The UK charity Cancerbackup provides general information about
cancer, and more specific information about ovarian cancer
  MedlinePlus also provides links to other information about ovarian
cancer (in English and Spanish)
  The KEGG Pathway database provides pathway maps of known
molecular networks involved in a wide range of cellular processes
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